Leerink Partnrs Has Negative Forecast for ALGN Q1 Earnings

Align Technology, Inc. (NASDAQ:ALGN) – Investment analysts at Leerink Partnrs decreased their Q1 2025 earnings per share estimates for shares of Align Technology in a report issued on Wednesday, April 9th. Leerink Partnrs analyst M. Cherny now forecasts that the medical equipment provider will post earnings per share of $1.51 for the quarter, down from their previous estimate of $1.56. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Align Technology’s current full-year earnings is $7.98 per share. Leerink Partnrs also issued estimates for Align Technology’s FY2028 earnings at $11.35 EPS.

ALGN has been the subject of several other research reports. Mizuho decreased their price objective on Align Technology from $295.00 to $250.00 and set an “outperform” rating for the company in a report on Tuesday, March 25th. Jefferies Financial Group lowered their price target on shares of Align Technology from $285.00 to $260.00 and set a “buy” rating on the stock in a research report on Thursday, January 23rd. Morgan Stanley cut their price objective on shares of Align Technology from $280.00 to $272.00 and set an “overweight” rating for the company in a report on Thursday, February 6th. Leerink Partners raised shares of Align Technology from a “market perform” rating to an “outperform” rating and boosted their target price for the company from $235.00 to $280.00 in a report on Monday, January 6th. Finally, Wells Fargo & Company started coverage on Align Technology in a report on Friday, February 14th. They issued an “overweight” rating and a $255.00 price target for the company. One analyst has rated the stock with a sell rating, two have issued a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Align Technology has a consensus rating of “Moderate Buy” and a consensus price target of $262.64.

Align Technology Trading Down 3.0 %

NASDAQ:ALGN opened at $160.14 on Friday. Align Technology has a 12 month low of $141.74 and a 12 month high of $331.64. The firm’s 50 day moving average is $178.28 and its 200 day moving average is $207.89. The stock has a market capitalization of $11.72 billion, a PE ratio of 28.55, a price-to-earnings-growth ratio of 2.24 and a beta of 1.73.

Align Technology (NASDAQ:ALGN) last released its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.96 earnings per share for the quarter, missing the consensus estimate of $2.43 by ($0.47). Align Technology had a return on equity of 13.84% and a net margin of 10.54%.

Hedge Funds Weigh In On Align Technology

A number of hedge funds and other institutional investors have recently modified their holdings of ALGN. Neo Ivy Capital Management purchased a new stake in Align Technology in the third quarter worth approximately $32,000. Picton Mahoney Asset Management boosted its stake in shares of Align Technology by 69.9% in the 4th quarter. Picton Mahoney Asset Management now owns 141 shares of the medical equipment provider’s stock valued at $30,000 after purchasing an additional 58 shares in the last quarter. GKV Capital Management Co. Inc. purchased a new position in Align Technology in the 4th quarter worth $31,000. Aster Capital Management DIFC Ltd bought a new stake in Align Technology in the fourth quarter worth $35,000. Finally, Private Trust Co. NA boosted its position in Align Technology by 113.4% during the fourth quarter. Private Trust Co. NA now owns 175 shares of the medical equipment provider’s stock valued at $36,000 after buying an additional 93 shares during the period. 88.43% of the stock is currently owned by hedge funds and other institutional investors.

Align Technology Company Profile

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.